Calidi Biotherapeutics, Inc. (CLDI)
NYSEAMERICAN: CLDI · IEX Real-Time Price · USD
0.201
+0.008 (4.15%)
May 2, 2024, 4:00 PM EDT - Market closed
Calidi Biotherapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
41
Market Cap
9.84M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 0 | - | - |
Dec 31, 2022 | 45.00K | -404.00K | -89.98% |
Dec 31, 2021 | 449.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCLDI News
- 1 day ago - Calidi Biotherapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting - Business Wire
- 9 days ago - Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on April 24 - Business Wire
- 13 days ago - Calidi Biotherapeutics, Inc. Announces Closing of $6.1 Million Public Offering - Business Wire
- 16 days ago - Calidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public Offering - Business Wire
- 23 days ago - Calidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Company's Novel Immunotherapies at the AACR Annual Meeting 2024 - Business Wire
- 6 weeks ago - Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Operating and Financial Results - Business Wire
- 7 weeks ago - Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine (CIRM) to Advance CLD-101 (NeuroNova) in Ovarian Cancer - Business Wire
- 2 months ago - Calidi Biotherapeutics to Highlight Novel Systemic Enveloped Oncolytic Virotherapy Platform Designed to Target All Tumor Sites at Upcoming Conference - Business Wire